December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Conjunctival Hyperemia With Latanoprost, Travoprost and Bimatoprost
Author Affiliations & Notes
  • AE Albritton
    Coordination Pharmaceutical Research Corp Charleston SC
  • JA Stewart
    Pharmaceutical Research Corporation Charleston SC
  • JN Leech
    Pharmaceutical Research Corporation Charleston SC
  • AL Jackson
    Pharmaceutical Research Corporation Charleston SC
  • WC Stewart
    Carolina Eye Institute University of South Carolina School of Medicine Columbia SC
  • Footnotes
    Commercial Relationships    A.E. Albritton, Pharmacia Corp F, R; J.A. Stewart, Pharmacia Corp. F, R; J.N. Leech, Pharmacia F, R; A.L. Jackson, Pharmacia Corp. F, R; W.C. Stewart, Pharmacia Corp F, R.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4112. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      AE Albritton, JA Stewart, JN Leech, AL Jackson, WC Stewart; Conjunctival Hyperemia With Latanoprost, Travoprost and Bimatoprost . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4112.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate conjunctival hyperemia between latanoprost 0.005%, bimatoprost 0.03% and travoprost 0.004% in healthy individuals. Methods: We evaluated conjunctival hyperemia, by a standard photographic measure grade (0-4), at the slit lamp in healthy subjects after dosing for five days with either latanoprost, bimatoprost or travoprost. Conjunctival hyperemia was evaluated at 24 hour trough (Hour 0) and at Hour 1 after dosing. Results: Twenty-eight subjects completed this study. From baseline slit lamp mean grade was 0.77 0.68, at 24 hours after dosing the grade for latanoprost was 1.36 0.87, bimatoprost 1.89 0.83, and travoprost 1.61 0.83. One hour after dosing the grade was 1.18 0.82 for latanoprost, 1.43 0.74 for bimatoprost and 1.64 0.87 for travoprost. Several comparisons were noted to be significant between groups by slit lamp biomicroscopy: first, at Hour 0 latanoprost had significantly less hyperemia than bimatoprost; second, at Hour 0 latanoprost showed significantly less change than bimatoprost compared to the study baseline (Visit 2); third, at Hour 1 latanoprost had significantly less hyperemia than travoprost; fourth, at Hour 1 latanoprost demonstrated significantly less change in hyperemia than travoprost from baseline (Visit 2); fifth, at Hour 1 latanoprost had less change in hyperemia than bimatoprost or travoprost between the study and the non-study eye (P = 0.03); and last, at Hour 1 latanoprost showed significantly less change than bimatoprost and travoprost compared to Hour 0 (P = 0.04). Subjects complained less about other people noticing their red eye with latanoprost than bimatoprost or travoprost (P = 0.048). No serious adverse events were noted. Conclusion: This study suggests that latanoprost may cause less short-term conjunctival hyperemia on average than travoprost or bimatoprost in healthy subjects.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 354 clinical (human) or epidemiologic studies: prevalence/incidence • 353 clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×